Table 3

Patient characteristics of new-user GLP-1RA cohort before and after propensity score matching

GLP-1RA new user cohort before propensity score matchingGLP-1RA new user cohort after propensity score matching
GLP-1RA
(n=501)
SU
(n=16 409)
GLP-1RA
(n=488)
SU
(n=488)
Age in years (SD)49.4 (11.3)57.8 (12.9)49.7 (11.2)49.2 (12.6)
Female204 (40.7%)6021 (36.7%)198 (40.6%)174 (35.7%)
Measure of deprivation
 Least40 (8%)1688 (10.3%)40 (8.2%)29 (5.9%)
 Most56 (11.2%)1770 (10.8%)56 (11.5%)52 (10.7%)
 Unknown240 (47.9%)6784 (41.3%)230 (47.1%)214 (43.9%)
Diabetes duration in years (SD)1.7 (1.6)1.2 (1.6)1.7 (1.6)1.7 (1.8)
Body mass index >30470 (93.8%)10 481 (63.9%)458 (93.9%)452 (92.6%)
No of hospitalisations in year prior to cohort entry
 0456 (91%)14 170 (86.4%)445 (91.2%)437 (89.5%)
 129 (5.8%)1344 (8.2%)28 (5.7%)27 (5.5%)
 210 (2%)499 (3%)9 (1.8%)17 (3.5%)
 3+6 (1.2%)396 (2.4%)6 (1.2%)7 (1.4%)
No of drugs in year prior to cohort entry
 0–417 (3.4%)1660 (10.1%)17 (3.5%)18 (3.7%)
 5–10195 (38.9%)7899 (48.1%)192 (39.3%)208 (42.6%)
 11+289 (57.7%)6850 (41.7%)279 (57.2%)262 (53.7%)
HbA1c
<6.5%66 (13.2%)1085 (6.6%)62 (12.7%)66 (13.5%)
 6.5%–7.5%99 (19.8%)2593 (15.8%)97 (19.9%)99 (20.3%)
 7.5%–9%150 (29.9%)5357 (32.6%)145 (29.7%)134 (27.5%)
 9%+179 (35.7%)7068 (43.1%)177 (36.3%)178 (36.5%)
 Unknown7 (1.4%)306 (1.9%)7 (1.4%)11 (2.3%)
eGFR <6036 (7.2%)2821 (17.2%)35 (7.2%)40 (8.2%)
Diagnoses in year prior to cohort entry
 Heart failure5 (1%)244 (1.5%)5 (1%)6 (1.2%)
 Hypertension107 (21.4%)3398 (20.7%)106 (21.7%)104 (21.3%)
 Dyslipidaemia16 (3.2%)771 (4.7%)16 (3.3%)23 (4.7%)
 Ischaemic heart disease11 (2.2%)644 (3.9%)11 (2.3%)9 (1.8%)
 Peripheral vascular diseaseS106 (<1%)SS
Prescription drug use in year prior to cohort entry
 Metformin457 (91.2%)13 542 (82.5%)445 (91.2%)449 (92%)
 AcarboseS7(<1%)SS
 SGLT2 inhibitors5 (1%)87(<1%)5 (1%)5 (1%)
 Meglitinide11 (2.2%)39(<1%)10 (2%)10 (2%)
 Thiazolidinedione38 (7.6%)376 (2.3%)38 (7.8%)41 (8.4%)
 Insulin65 (13%)307 (1.9%)55 (11.3%)59 (12.1%)
 Hypnotic32 (6.4%)1093 (6.7%)32 (6.6%)35 (7.2%)
 Mood10 (2%)228 (1.4%)10 (2%)8 (1.6%)
 Anticonvulsant33 (6.6%)682 (4.2%)31 (6.4%)32 (6.6%)
 Antipsychotics12 (2.4%)507 (3.1%)12 (2.5%)12 (2.5%)
  • S, suppressed due to low number of events.

  • DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin A1c; SGLT2, sodium-dependent glucose cotransporter-2; SU, sulfonylureas.